<DOC>
	<DOCNO>NCT00037102</DOCNO>
	<brief_summary>The participant receive weekly intramuscular treatment AVONEX® ( interferon beta 1-a ) bi-monthly high dose intravenous methotrexate Leucovorin rescue .</brief_summary>
	<brief_title>Combination Therapy With Avonex BiMonthly High Dose Intravenous Methotrexate Multiple Sclerosis</brief_title>
	<detailed_description>The participant receive weekly intramuscular treatment AVONEX® ( interferon beta 1-a ) bi-monthly high dose intravenous methotrexate Leucovorin rescue . Entrance study base Multiple Sclerosis Functional Composite Score ( MSFC ) evaluation -4 month , - 1 month prior study , decrease score note . The composite score consist Timed 25-Foot Walk , Nine-Hole Peg Test ( 9HPT ) , Paced Auditory Serial Addition Test 3 ( PASAT 3 ) . The patient must AVONEX® least 6 month . At study entrance , baseline lab work ( complete blood count , platelet count , routine electrolyte , blood urea nitrogen , creatinine , liver function test , 24 hour urine collection creatinine clearance , urine pH ) , electrocardiogram ( measurement heart activity ) serum pregnancy test do . A complete physical examination perform , include measurement vital sign ( heart rate blood pressure ) , well magnetic resonance imaging ( MRI ) document status disease . A self-administered questionnaire , MSQLI ( Multiple Sclerosis Quality Life Instrument ) , complete baseline end study . MSFC safety evaluation ( previously mention blood urine test electrocardiograms ( EKG ) , conduct throughout study month 2 , 4 , 6 , 8 , 10 , 12 . Blood test immune cell also draw visit . The patient continue regimen treatment discretion cost , outside parameter study , apparent efficacy without serious adverse event . This treatment would supervision Dr. Rowe . The patient continue AVONEX® intramuscular injection 30 microgram ( administer patient caregiver ) weekly basis schedule intravenous high dose methotrexate 2 Gm/m2 follow intravenous oral leucovorin rescue every 2 month . The methotrexate infusion perform outpatient infusion center . The patient require complete patient diary course trial , participate keep scheduled appointment , inform research staff physician change concomitant medication adverse event may experience .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>To eligible entry study , candidate must meet following eligibility criterion time enrollment : Between age 18 60 year , inclusive . Diagnosis clinically definite relapse MS. Must AVONEX® therapy least six month . Brain MRI scan demonstrate lesion consistent MS. Subject must least one clinical exacerbation last year , must occur AVONEX® therapy least six twelve ( 612 ) month . A clinical exacerbation define decrease 0.1 MSFC composite subset domain score administer 3 month apart . Give write informed consent prior test protocol , include screen test evaluation consider part subject 's routine care . To eligible treatment methotrexate , subject must evidence MS disease activity baseline screen MRI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2003</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>AVONEX</keyword>
	<keyword>interferon beta 1a</keyword>
	<keyword>demyelinate</keyword>
	<keyword>autoimmune</keyword>
</DOC>